Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Monday, up 4.22% from the previous trading day, before settling in for the closing price of $18.24. Over the past 52 weeks, NRIX has traded in a range of $7.65-$29.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 38.34% over the past five years. While this was happening, its average annual earnings per share was recorded -6.03%. With a float of $68.89 million, this company’s outstanding shares have now reached $70.84 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees. In terms of profitability, gross margin is 71.85%, operating margin of -343.3%, and the pretax margin is -313.19%.
Nurix Therapeutics Inc (NRIX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 2.74%, while institutional ownership is 95.11%. The most recent insider transaction that took place on Jan 02 ’25, was worth 112,295. In this transaction Chief Legal Officer of this company sold 5,760 shares at a rate of $19.50, taking the stock ownership to the 28,084 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Officer proposed sale 5,760 for $18.84, making the entire transaction worth $108,518.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.03% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 5.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.81 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 0.67 million, a negative change from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 47.96%. Additionally, its Average True Range was 1.21.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 12.52%, which indicates a significant decrease from 48.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.79% in the past 14 days, which was lower than the 54.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.95, while its 200-day Moving Average is $20.31. Nevertheless, the first resistance level for the watch stands at $19.59 in the near term. At $20.18, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.22. If the price goes on to break the first support level at $17.96, it is likely to go to the next support level at $16.92. Assuming the price breaks the second support level, the third support level stands at $16.33.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 70,836K Shares Outstanding. Its annual sales at the moment are 76,990 K in contrast with the sum of -143,950 K annual income. Company’s last quarter sales were recorded 12,590 K and last quarter income was -48,960 K.
